Methods of Treating Colorectal Cancer

Abstract

Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer.

1 . A method of treating colorectal cancer in a patient suffering from colorectal cancer, the method comprising administering to the patient an effective amount of a SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 10 to the patient. 
     
     
         2 . A method of inhibiting the growth of colorectal cancer cells, comprising inhibiting SMAD7 in the colorectal cancer cells. 
     
     
         3 . A method of treating colorectal cancer or inhibiting the growth of colorectal cancer cells in a patient suffering from colorectal cancer, the method comprising administering to the patient an effective amount of a SMAD7 antisense oligonucleotide comprising the nucleotide sequence of SEQ ID NO: 10. 
     
     
         4 - 7 . (canceled) 
     
     
         8 . The method  claim 1 , wherein the SMAD7 antisense oligonucleotide is administered parenterally. 
     
     
         9 . The method of  claim 1 , wherein the SMAD7 antisense oligonucleotide is administered orally. 
     
     
         10 . The method of  claim 3 , wherein said administering comprises administering a pharmaceutical composition comprising the SMAD7 antisense oligonucleotide and a pharmaceutically acceptable carrier. 
     
     
         11 - 13 . (canceled) 
     
     
         14 . The method of  claim 10 , wherein the pharmaceutical composition is administered parenterally. 
     
     
         15 . The method of  claim 10 , wherein the pharmaceutical composition is administered orally. 
     
     
         16 . The method of  claim 15 , wherein the pharmaceutical composition comprises an enteric coating comprising an ethylacrylate-methacrylic acid copolymer. 
     
     
         17 . The method of  claim 1 , wherein the patient is a human. 
     
     
         18 . The method of  claim 1 , comprising administering at least 100 μg of the SMAD7 antisense oligonucleotide. 
     
     
         19 . The method of  claim 18 , comprising administering from 35 mg to 500 mg of the SMAD7 antisense oligonucleotide. 
     
     
         20 . The method of  claim 3 , wherein the patient is a human. 
     
     
         21 . The method of  claim 3 , comprising administering at least 100 μg of the SMAD7 antisense oligonucleotide. 
     
     
         22 . The method of  claim 21 , comprising administering from 35 mg to 500 mg of the SMAD7 antisense oligonucleotide. 
     
     
         23 . The method of  claim 1 , wherein all of the internucleoside bonds of the nucleotide sequence of SEQ ID NO: 10 are phosphorothioate bonds. 
     
     
         24 . The method of  claim 3 , wherein all of the internucleoside bonds of the nucleotide sequence of SEQ ID NO: 10 are phosphorothioate bonds.